BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 21630065)

  • 1. Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians.
    Potter BK; Little J; Chakraborty P; Kronick JB; Evans J; Frei J; Sutherland SC; Wilson K; Wilson BJ
    J Inherit Metab Dis; 2012 Jan; 35(1):115-23. PubMed ID: 21630065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of newborn screening for fatty acid oxidation disorders on neurological outcome: A Belgian retrospective and multicentric study.
    Everard E; Laeremans H; Boemer F; Marie S; Vincent MF; Dewulf JP; Debray FG; De Laet C; Nassogne MC
    Eur J Paediatr Neurol; 2024 Mar; 49():60-65. PubMed ID: 38377647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD.
    Elizondo G; Matern D; Vockley J; Harding CO; Gillingham MB
    Mol Genet Metab; 2020; 131(1-2):90-97. PubMed ID: 32928639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-chain fatty acid oxidation during early human development.
    Oey NA; den Boer ME; Wijburg FA; Vekemans M; Augé J; Steiner C; Wanders RJ; Waterham HR; Ruiter JP; Attié-Bitach T
    Pediatr Res; 2005 Jun; 57(6):755-9. PubMed ID: 15845636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial fatty acid beta-oxidation in the human eye and brain: implications for the retinopathy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
    Tyni T; Paetau A; Strauss AW; Middleton B; Kivelä T
    Pediatr Res; 2004 Nov; 56(5):744-50. PubMed ID: 15347768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
    Yamada K; Taketani T
    J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts.
    Roe DS; Yang BZ; Vianey-Saban C; Struys E; Sweetman L; Roe CR
    Mol Genet Metab; 2006 Jan; 87(1):40-7. PubMed ID: 16297647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of 3-hydroxy-fatty acids in the culture medium of long-chain L-3-hydroxyacyl CoA dehydrogenase (LCHAD) and mitochondrial trifunctional protein-deficient skin fibroblasts: implications for medium chain triglyceride dietary treatment of LCHAD deficiency.
    Jones PM; Butt Y; Bennett MJ
    Pediatr Res; 2003 May; 53(5):783-7. PubMed ID: 12621125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-specific strategies of the very-long chain acyl-CoA dehydrogenase-deficient (VLCAD-/-) mouse to compensate a defective fatty acid β-oxidation.
    Tucci S; Herebian D; Sturm M; Seibt A; Spiekerkoetter U
    PLoS One; 2012; 7(9):e45429. PubMed ID: 23024820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle MRI in patients with long-chain fatty acid oxidation disorders.
    Diekman EF; van der Pol WL; Nievelstein RA; Houten SM; Wijburg FA; Visser G
    J Inherit Metab Dis; 2014 May; 37(3):405-13. PubMed ID: 24305961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of Lipistart, a medium-chain triglyceride based formula, in the dietary treatment of long-chain fatty acid disorders: a phase I study.
    MacDonald A; Webster R; Whitlock M; Gerrard A; Daly A; Preece MA; Evans S; Ashmore C; Chakrapani A; Vijay S; Santra S
    J Pediatr Endocrinol Metab; 2018 Mar; 31(3):297-304. PubMed ID: 29425111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very long-chain acyl-CoA dehydrogenase (VLCAD-) deficiency-studies on treatment effects and long-term outcomes in mouse models.
    Tucci S
    J Inherit Metab Dis; 2017 May; 40(3):317-323. PubMed ID: 28247148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of earlier versus later dietary management in long-chain 3-hydroxyacyl-CoA dehydrogenase or mitochondrial trifunctional protein deficiency: a systematic review.
    Fraser H; Geppert J; Johnson R; Johnson S; Connock M; Clarke A; Taylor-Phillips S; Stinton C
    Orphanet J Rare Dis; 2019 Nov; 14(1):258. PubMed ID: 31730477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening.
    Kang E; Kim YM; Kang M; Heo SH; Kim GH; Choi IH; Choi JH; Yoo HW; Lee BH
    BMC Pediatr; 2018 Mar; 18(1):103. PubMed ID: 29519241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop.
    Spiekerkoetter U; Lindner M; Santer R; Grotzke M; Baumgartner MR; Boehles H; Das A; Haase C; Hennermann JB; Karall D; de Klerk H; Knerr I; Koch HG; Plecko B; Röschinger W; Schwab KO; Scheible D; Wijburg FA; Zschocke J; Mayatepek E; Wendel U
    J Inherit Metab Dis; 2009 Aug; 32(4):488-97. PubMed ID: 19399638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complicated peripartum course in a patient with very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency.
    Akar HT; Çağan M; Yıldız Y; Sivri HS
    Neuromuscul Disord; 2021 Jun; 31(6):566-569. PubMed ID: 33965301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV9 gene replacement therapy for respiratory insufficiency in very-long chain acyl-CoA dehydrogenase deficiency.
    Zieger M; Keeler AM; Flotte TR; ElMallah MK
    J Inherit Metab Dis; 2019 Sep; 42(5):870-877. PubMed ID: 30993714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
    Gillingham MB; Connor WE; Matern D; Rinaldo P; Burlingame T; Meeuws K; Harding CO
    Mol Genet Metab; 2003 Jun; 79(2):114-23. PubMed ID: 12809642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological outcome in long-chain hydroxy fatty acid oxidation disorders.
    Mütze U; Ottenberger A; Gleich F; Maier EM; Lindner M; Husain RA; Palm K; Beblo S; Freisinger P; Santer R; Thimm E; Vom Dahl S; Weinhold N; Grohmann-Held K; Haase C; Hennermann JB; Hörbe-Blindt A; Kamrath C; Marquardt I; Marquardt T; Behne R; Haas D; Spiekerkoetter U; Hoffmann GF; Garbade SF; Grünert SC; Kölker S
    Ann Clin Transl Neurol; 2024 Apr; 11(4):883-898. PubMed ID: 38263760
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.